- Enarson DA. Controlling tuberculosis—is it really feasible? Tuberc Lung Dis 2000; 80 : 57–9.
- Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999; 353: 444–9.
- Orme IM, Collins FM. Mouse model of tuberculosis. In: Bloom BR, ed. Tuberculosis: protection, pathology, and control. Washington, DC: ASM Press, 1994: 113–34.
- Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29–35.
- Fine PEM, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med 1999; 341: 1226–7.
- O’Brien RJ. Preventive therapy for tuberculosis. In: Porter JDH, McAdam PWJ, eds. Tuberculosis. Back to the future. Chichester: Wiley, 1994: 151–70.
- McKinney JD, Honer zu Bentrop K, Munoz-Elias EJ, Miczak A, Chen B, Chan WT, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyxolate shunt enzyme isocitrate lase. Nature 2000; 406: 735–8.
- Glickman MS, Cox JS, Jacobs WR Jr. A novel mycolic acid cyclopropane synthetase is required for coding, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 2000; 5: 717–27.
- Stewart GR, Snewin VA, Tormay P, O’Gaora P, Goyal M, Betts J, et al. Overexpression of heat shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Submitted for publication.
- Lowrie DB, Tascon RE, Bonato VLD, Lima VMF, Faccioli LH, Stavropoulos E, et al. Therapy of tuberculosis in mice by DNA vaccination. Nature 1999; 400: 269–71.
Scandinavian Journal of Infectious Diseases
Volume 33, 2001 - Issue 1